This high-risk sector is one ALL new investors should avoid

Australia's fledging biotech sector, filled with the likes of Cynata Therapeutics Ltd (ASX:CYP) and Pharmaxis Ltd (ASX:PXS) is not for the faint-hearted.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If there's one sector that all fledgling investors should avoid, it's the biotechnology/medical research segment. The combination of unprofitable businesses and continuous Research and Development (R&D) spending with uncertain outcomes is not good news for your investment returns.

Most investors entering the sector lack the expertise to really evaluate a company's scientific claims/research updates, and are enticed in by the potential 'billion dollar' markets of stem cell research, new life-saving drugs, and so on.

Many companies in the sector, like Cynata Therapeutics Ltd (ASX: CYP) and Pharmaxis Ltd (ASX: PXS), have little money-earning potential when they get started. They use a sexy story to attract enough shareholder cash to fund early stage research which may or may not result in a saleable treatment many years down the line.

The trouble is that research companies can run out of cash several times during the course of their development and have to solicit more from shareholders, which is quite difficult with nothing to show in revenues. Many who comment on the sector suspect companies occasionally 'play up' or exaggerate their progress so far, or the ultimate potential of their research, in order to pump up the share price for a capital raising (issue of new shares to raise funds) further down the line.

There's also no safe way to exit the business or recover expended costs should research prove fruitless. A company can't very well say "well, we've got a treatment in Phase 2 that's 3 years and $15 million dollars away from maybe being approved for use on humans" and expect to achieve an attractive price for all the millions of dollars spent reaching that point.

Shareholders trying to get out are also vulnerable to share price movements, because these companies are often quite small and illiquid.

Even businesses like Mesoblast Limited (ASX: MSB), once seen as one of the more promising prospects in the sector, are vulnerable to this vicious cycle of capital raisings, investor excitement, and subsequent disillusionment.

That's not to say that all businesses in the biotech/medical research sector are terrible investments. CSL Limited (ASX: CSL) is surely the shining light that all biotechs aspire to follow, while Sirtex Medical Limited (ASX: SRX) is also an attractive prospect. Every now and then something like Medical Developments International Ltd (ASX: MVP) shoots into the spotlight on the back of a successful treatment, but for every Medical Developments, there must be a dozen Prima BioMed Limited's (ASX: PRR).

Novice investors beware.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »